Evgeny Alekseevich Stepanov

Evgeny Alekseevich Stepanov

Auto-generated profile, based on publicly available information

Evgeny Alekseevich Stepanov

Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
ISIlya Schastlivtsev
Ilya Schastlivtsev
APAleksey Pankov
Aleksey Pankov
STSergey Tsaplin
Sergey Tsaplin
ESEvgeny Stepanov
Evgeny Stepanov
SZSergey Zhuravlev
Sergey Zhuravlev
KLKirill Lobastov
Kirill Lobastov
Objectives: To assess the efficacy and safety of rivaroxaban compared to warfarin after inferior vena cava (IVC) filter implantation. Method: This retrospective analysis includes data from 100 patients with deep vein thrombosis (DVT) who underwent IVC filter implantation due to a free-floating thrombus (n = 64), thrombus propagation (n = 8), or acute bleeding (n = 8) on therapeutic anticoagulation, catheter-directed thrombolysis (n = 8), or had previously implanted filter with DVT recurrence. Patients were treated with warfarin (n = 41) or rivaroxaban (n = 59) for 3-12 months. Symptomatic venous thromboembolism (VTE) recurrence and bleeding events were assessed at 12 months follow-up. Results: Three (7.3%) cases of VTE recurrence without IVC filter occlusion occurred on warfarin and none on rivaroxaban. The only (2.4%) major bleeding occurred on warfarin. Three (5.1%) clinically relevant non-major bleedings were detected on rivaroxaban. No significant differences existed between groups when full and propensity scores matched datasets were compared. Conclusions: Rivaroxaban seems not less effective and safe than warfarin after IVC filter implantation.

26 November 2020 in Hirurg (Surgeon)
Verified
Journal Article
Closed access
DPD. V. Plotkin
D. V. Plotkin
MRMikhail Reshetnikov
Mikhail Reshetnikov
MSM. V. Sinitsyn
M. V. Sinitsyn
YZYu. R. Zyuzya
Yu. R. Zyuzya
TAT. I. Abu Arqoub
T. I. Abu Arqoub
ESE. A. Stepanov
E. A. Stepanov
The term granulomatous peritonitis encompasses a wide range of unusual forms of inflammation of the peritoneum that have simmilar clinical, pathological, and imaging features. Infectious agents such as mycobacteria, fungi, foreign substances such as talc and barium; meconium; intestinal contents; contents of a ruptured ovarian cyst; gall stones; nematode eggs or unknown agents can cause granulomatous peritonitis. Most of the listed nosological forms of peritoneal lesions are not described, whereas vessels, lung tissue, intestines, kidneys, liver, lymph nodes are often the target organs. So far there are very fewpapers in the medical literature covering questions such as the spreading of granulomatous peritonitis, methods of their diagnosis, differential diagnosis and treatment. This review is an attempt to fill this gap.

14 February 2022 in Hirurg (Surgeon)
Verified
Journal Article
Closed access
PUPirogov’s Russian National Research Medical University
Pirogov’s Russian National Research Medical University
KLKirill Lobastov
Kirill Lobastov
ESEvgeny Alekseevich Stepanov
Evgeny Alekseevich Stepanov
STSergey Nikolaevich Tsaplin
Sergey Nikolaevich Tsaplin
ISIlya Veniaminovich Schastlivtsev
Ilya Veniaminovich Schastlivtsev
GRGrigory Vladimirovich Rodoman
Grigory Vladimirovich Rodoman
The aim of the study was to evaluate the efficacy and safety of increased doses of anticoagulants in comparison with standard doses in inpatients with COVID-19. Material and methods. A systematic review was carried out in October 2021 using the Pubmed database. The analysis included only randomized clinical trials with ≥200 participants that reported the death rate as the total number of cases or the percentage of patients. The primary outcome was all-cause mortality within the observation period. Additionally, the risk of arterial and venous thrombotic events, major and clinically relevant non-major bleeding was assessed. Results. Searching of Pubmed identified 8,903 references, of which the results of 6 randomized clinical trials (INSPIRATION, 3 platforms study in REMAP-CAP, ACTIV-4a, and ATTACC including stable and unstable patients, RAPID, ACTION and HEP-COVID) with the total of 5,228 patients were included in the final qualitative analysis and quantitative synthesis. Among all the patients, 2,660 received increased doses and 2,568 — standard doses of anticoagulants. The follow-up period varied from 21 to 30 days. The administration of increased doses did not affect the risk of death (OR, 0.95; 95 % CI, 0.73–1.24; I² = 59.14 %), but was associated with a reduced risk of thrombotic events (OR, 0.56; 95 % CI, 0.43–0.73; I² = 24.90 %), and an increased risk of major bleeding (OR, 1.86; 95 % CI, 1.23–2.80; I² = 0.00 %) or clinically relevant non-major bleeding (OR, 3.66; 95 % CI, 1.65–8.10; I² = 0.00 %). Within the sensitivity analysis, similar results were obtained in the subgroups of critically ill or stable patients and individuals with increased D-dimer. The maximal reduction in the risk of thrombotic events was found for the subgroup of patients with increased D-dimer (OR, 0.48; 95 % CI, 0.34–0.70; I² = 36.38 %). Conclusions. The use of increased doses of anticoagulants in inpatients with COVID-19 does not reduce the risk of death. Still, it is associated with a decrease in the risk of arterial and venous thrombosis and an increased risk of major bleeding.

26 November 2020 in Hirurg (Surgeon)
Verified
Journal Article
Closed access
DPD. V. Plotkin
D. V. Plotkin
MRMikhail Reshetnikov
Mikhail Reshetnikov
MSM. V. Sinitsyn
M. V. Sinitsyn
YZYu. R. Zyuzya
Yu. R. Zyuzya
TAT. I. Abu Arqoub
T. I. Abu Arqoub
ESE. A. Stepanov
E. A. Stepanov
The term granulomatous peritonitis encompasses a wide range of unusual forms of inflammation of the peritoneum that have simmilar clinical, pathological, and imaging features. Infectious agents such as mycobacteria, fungi, foreign substances such as talc and barium; meconium; intestinal contents; contents of a ruptured ovarian cyst; gall stones; nematode eggs or unknown agents can cause granulomatous peritonitis. Most of the listed nosological forms of peritoneal lesions are not described, whereas vessels, lung tissue, intestines, kidneys, liver, lymph nodes are often the target organs. So far there are very fewpapers in the medical literature covering questions such as the spreading of granulomatous peritonitis, methods of their diagnosis, differential diagnosis and treatment. This review is an attempt to fill this gap.